NanoViricides, Inc. (NNVC)

USD 1.5

(0.67%)

Revenue Summary of NanoViricides, Inc.

  • NanoViricides, Inc.'s latest annual revenue in 2024 was - USD , down 0.0% from previous year.
  • NanoViricides, Inc.'s latest quarterly revenue in 2024 Q4 was - USD , down 0.0% from previous quarter.
  • NanoViricides, Inc. reported a annual revenue of - USD in annual revenue 2023, down 0.0% from previous year.
  • NanoViricides, Inc. reported a annual revenue of - USD in annual revenue 2022, down 0.0% from previous year.
  • NanoViricides, Inc. reported a quarterly revenue of - USD for 2024 Q4, down 0.0% from previous quarter.
  • NanoViricides, Inc. reported a quarterly revenue of - USD for 2024 Q3, down 0.0% from previous quarter.

Annual Revenue Chart of NanoViricides, Inc. (2024 - 2005)

Historical Annual Revenue of NanoViricides, Inc. (2024 - 2005)

Year Revenue Revenue Growth
2024 - USD 0.0%
2023 - USD 0.0%
2022 - USD 0.0%
2021 - USD 0.0%
2020 - USD 0.0%
2019 - USD 0.0%
2018 - USD 0.0%
2017 - USD 0.0%
2016 - USD 0.0%
2015 - USD 0.0%
2014 - USD 0.0%
2013 - USD 0.0%
2012 - USD 0.0%
2011 - USD 0.0%
2010 - USD 0.0%
2009 - USD 0.0%
2008 - USD 0.0%
2007 - USD 0.0%
2006 - USD 0.0%
2005 - USD 0.0%

Peer Revenue Comparison of NanoViricides, Inc.

Name Revenue Revenue Difference
AIM ImmunoTech Inc. 202 Thousand USD 100.0%
Ampio Pharmaceuticals, Inc. - USD NaN%
Armata Pharmaceuticals, Inc. 4.52 Million USD 100.0%
Actinium Pharmaceuticals, Inc. 81 Thousand USD 100.0%
Azitra, Inc. 686 Thousand USD 100.0%
Can-Fite BioPharma Ltd. 743 Thousand USD 100.0%
Chromocell Therapeutics Corporation - USD NaN%
Calidi Biotherapeutics, Inc. - USD NaN%
CEL-SCI Corporation - USD NaN%
iBio, Inc. 225 Thousand USD 100.0%
Lineage Cell Therapeutics, Inc. 8.94 Million USD 100.0%
MAIA Biotechnology, Inc. - USD NaN%
Matinas BioPharma Holdings, Inc. 1.09 Million USD 100.0%
Navidea Biopharmaceuticals, Inc. 65.65 Thousand USD 100.0%
NovaBay Pharmaceuticals, Inc. 14.72 Million USD 100.0%
Oragenics, Inc. 37.65 Thousand USD 100.0%
BiomX Inc. -357 Thousand USD 100.0%
BiomX Inc. -357 Thousand USD 100.0%
Protalix BioTherapeutics, Inc. 65.49 Million USD 100.0%
Palatin Technologies, Inc. 4.49 Million USD 100.0%
Scorpius Holdings, Inc. 6.99 Million USD 100.0%